Cited by 60Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets

Open access
Dalal, Mehul R., Grabner, Michael, Bonine, Nicole, Stephenson, Judith J., DiGenio, Andres, Bieszk, Nella·2016·Diabetes Research and Clinical Practice

Abstract

AIMS: To investigate treatment patterns and achievement of glycemic targets in patients with type 2 diabetes mellitus treated with basal insulin in a real-world setting, and to determine physicians' beliefs and practices regarding these patients. METHODS: This study had two components; a retrospective analysis using a US claims database of patient and treatment data, and a survey of physicians' beliefs and practices. RESULTS: A total of 39,074 patients treated with basal insulin were included in this analysis. The proportion of patients achieving HbA1c<7.0% (53mmol/mol) was similar in ongoing basal insulin users at baseline (26%) and at 3months follow-up (27%). The number of new initiators achieving HbA1c<7.0% (53mmol/mol) increased from baseline (11%) to 3months (27%). In the physician survey component, the majority of physicians indicated they would continue to increase basal insulin dose as long as was needed to reach HbA1c/fasting blood glucose goals (85% of physicians treating 'not on-goal' patients, 78% of physicians treating 'on-goal' patients). Physician-perceived barriers to insulin intensification included patient's lifestyle, non-adherence, and concerns about out-of-pocket costs. CONCLUSIONS: A large proportion of patients on insulin-based therapy fail to reach glycemic goals. More education of clinicians may improve insulin intensification rates and increase the proportion of patients reaching glycemic targets.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.diabres.2016.08.004

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 24 · Cited by 60

Authors
Dalal, M. R., Grabner, M., Bonine, N., Stephenson, J. J., DiGenio, A., & Bieszk, N.
Affiliations
  • Takeda Oncology (United States) (US)
  • Carelon Research (United States) (US)
  • Sanofi (United States) (US)
Corresponding author
Dalal, Mehul R.
Venue
Diabetes Research and Clinical Practice
Publisher
Elsevier BV
Published
2016-11
Volume
121
Pages
17-26
ISSN
0168-8227 (ISSN-L)
OpenAlex
W2517165909
Cited by
60
References
24
Citations by year
2026: 1 · 2025: 5 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 5 · 2020: 8 · 2019: 15 · 2018: 9 · 2017: 6
FWCI
10.02
Type
journal article
Language
en
Open access
Locations
  • Diabetes Research and Clinical Practice (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Sanofi US, Inc
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, basal insulin, glycemic control, HbA1c targets, insulin intensification, physician beliefs, treatment patterns, medication adherence, out-of-pocket costs, patient lifestyle
MeSH terms
Achievement, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Health Expenditures, Female, Goals, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Health Knowledge, Attitudes, Practice, Male, Middle Aged, Surveys and Questionnaires, Retrospective Studies, Databases, Factual, Glycemic Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review